The next generation of IPF endpoints: insights from the 10th IPF Summit

FVC remains central to assessing efficacy in idiopathic pulmonary fibrosis (IPF), but it does not tell the whole story. That was the theme that stood out most clearly at the 10th IPF Summit in Boston, which Vitalograph was proud to sponsor and contribute to. The industry-led meeting that brought together more than 150 stakeholders from across pulmonary fibrosis discovery, translational science and clinical development. 

IPF Summit Boston

The summit took place against a backdrop of positive Phase III readouts, emerging therapies and changing standards of care. Its focus was how IPF drug development can become smarter, faster and more meaningful for patients. Discussions explored how predictive preclinical packages, evolving clinical protocols and novel mechanisms could help the field move beyond slowing FVC decline towards improving patients' quality of life.

As background therapies slow disease progression, complementary endpoints may be needed to detect smaller, incremental benefits. In this article, we share Vitalograph's key takeaways for clinical trial design and endpoint strategy.

Key takeaways

  • FVC is here to stay. It remains the cornerstone endpoint, but its sensitivity is being questioned as background therapy slows progression.

  • Composite endpoints are gaining ground. Combining physiology, imaging, symptoms and patient-reported outcomes could reveal earlier or smaller treatment effects.

  • Complementary measures are maturing. Quantitative CT, oscillometry, cough measurement and patient-reported outcomes each offer a distinct perspective.

  • Data quality matters as much as new endpoints. Central review, ATS/ERS-compliant testing and structured quality management help separate treatment effects from measurement noise.

Pulmonary fibrosis clinical trials at a crossroads: are we moving beyond FVC? 

FVC featured in almost every study discussed at the summit, underlining its continued regulatory importance. However, when effective background therapy slows disease progression, questions remain about the sensitivity of FVC to capture all meaningful physiological change. 

A recurring question was whether reliance on FVC alone could miss improvements or stabilisation in other aspects of disease. Importantly, the discussion was not about replacing FVC. It was about adding measures that could provide a fuller picture of benefit and support future co-primary or composite endpoints.

What this means for study designers

For sponsors and study teams, this may include:

  • Ensuring high-quality spirometry.

  • Reducing measurement variability.

  • Using supplemental endpoints to improve sensitivity and confidence.

  • Exploring multimodal endpoint packages.

Why composite endpoints are gaining ground

Pulmonary fibrosis affects patients in ways that extend beyond lung function. Composite approaches that combine physiology, imaging, symptoms and patient-reported outcomes could provide a fuller view of progression across lung function, cough, exercise capacity and quality of life.

For trial sponsors, there is a further advantage: composite approaches may reveal earlier or smaller treatment effects that a single measure could miss.

The complementary endpoints to watch

Several measures are being explored as potential complements to FVC. They differ in maturity and supporting evidence, but each offers a distinct perspective on disease progression, treatment response or patient experience.

Quantitative imaging

Quantitative CT is among the more advanced candidates being explored as a complement to FVC. It provides an objective view of structural change and may offer greater sensitivity when progression is slow.

However, its value depends on consistent execution. Quantitative CT is expensive and not widely available, and many prospective sites may not have access to the required technology, creating challenges when studies need to scale. Differences in scanners, acquisition protocols and breath-hold technique can also introduce variability.

Early consideration of site access, standardisation and scalability may therefore be important. Central review, overreading and structured quality control may help improve consistency across trial sites.

Oscillometry

Oscillometry generally correlates with spirometry and, in some settings, may be more sensitive to progression. Long-term evidence in ILD is still limited, but the technique has several practical advantages:

  • Minimal patient effort.

  • Feasibility in advanced disease.

  • Sensitivity to small airway changes missed by spirometry.

  • Use in preclinical and clinical research.

Cough

Cough measurement was discussed in several potential roles:

  • Assessing therapeutic effectiveness through reductions in cough frequency.

  • Contributing to composite measures alongside patient-reported outcomes that capture its impact on daily life.

  • Providing better data on treatment-emergent cough, which is common with inhaled therapies.

Patient-reported outcomes

Patient-reported outcomes can show how changes in lung function translate into everyday experience. Future measures need to reflect what matters to patients, including pain, cough, breathlessness and quality of life, while connecting physiological change with meaningful benefit.

Key considerations included:

  • Selecting patient-centred outcomes.

  • Involving patients in endpoint development.

  • Aligning physiological outcomes with patient experience.

  • Showing meaningful benefit beyond preserving lung function.

Better data may matter as much as new endpoints

Identifying new endpoints is only part of the challenge. Improving the quality of established measures may be just as important.

Central review, ATS/ERS-compliant testing, overreading and structured quality management can help reduce variability. That makes it easier for smaller, targeted or adaptive trials to distinguish potential treatment effects from measurement noise.

Looking ahead

FVC is likely to remain the cornerstone endpoint for pulmonary fibrosis clinical trials, while increasingly sitting alongside measures such as imaging, oscillometry, cough assessment and patient-reported outcomes. Used together, these measures may capture the multiple dimensions of pulmonary fibrosis progression more effectively.

As care improves and treatment effects become harder to detect, future trials may benefit from a broader set of measures that are sensitive to change and supported by consistent delivery and robust quality management.

Want to explore cough as an endpoint in more depth? Read our article Why cough counts in pulmonary fibrosis research.

Talk to our team